Date: September 7-9, 2026
Location: InterContinental Barcelona
Event Website: https://www.phacilitate.com/advanced-therapies-europe
Meet our team!
Be sure to visit our panel or request a meeting with our team to discover how our global network and capabilities can accelerate your product to the next stage.
REQUEST A MEETING
Attend our panel:
Panel: Access Is the Real Innovation: How Europe turns breakthroughs into therapies patients can actually receive.
Date/Time: September 9th from 13.00-13.30 (CEST) | 07:00 – 07:30 (EDT)
Location: Theatre 1
Moderator: Mark Flower, VP Business Development, Cell & Gene Technology, AGC Biologics
Panelists:
-
Alessandra Magnani, Head of Advanced Therapies, Hospital Sant Joan de Deu
-
Marion Hitchcock, Managing Director, Bayer
-
Ingrid Marchal-Gerez, Director EMEA Cell Therapy Commercial Operations, Johnson & Johnson
Key Takeaways:
-
System-level access models — How Europe can build coordinated, multi-stakeholder access frameworks that connect developers, regulators, payers, and delivery systems to turn scientific breakthroughs into real-world treatment pathways.
-
Scaling innovation across diverse health systems — Why Europe must rethink incentives, governance, and cross-border alignment to make ATMP access viable and sustainable across 27 different national infrastructures.
-
Partnership as the operating model — Which collaboration structures between industry, regulators, payers, and health systems are most likely to succeed, and why access cannot be solved by any single stakeholder acting alone.
-
The economics of access — The real financial, operational, and policy constraints behind expanding access to advanced therapies — and how organizations are navigating them without slowing innovation or compromising patient outcomes.
LEARN ABOUT OUR PROTEIN-BASED BIOLOGICS AND ADVANCED THERAPIES
Mammalian Bioprocessing Systems
We have several decades of experience with mammalian-based bioprocessing production, and can support your project from cell line development through full-scale commercialization. We offer a variety of flexible single-use manufacturing scales with options for multiple configurations at our sites in the U.S., Europe, and Japan.
Mammalian Services
Microbial Bioprocessing Systems
We have produced 100+ products using microbial expressed proteins and multiple modes of expression - including secretion (yeast), periplasmic secretion, soluble intracellular expression, and inclusion bodies, also from initial development through full-scale. commercialization. Our expertise includes experience with E. Coli, Pichia, Pseudomonas Fluorescens, Bacillus microbial expression systems, and more.
We use standard industry systems, including batch and fed-batch methods, to produce microbial drug products, and offer cell banking services that meet the standards of regulatory agencies worldwide, and flexible manufacturing scales to support any stage of your product lifecycle.
Microbial Services
Cell Therapy Production and Manufacturing
AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan facility, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.
Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting.
Cell Therapy Offering
Viral Vector Production and Manufacturing
AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV).
Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house.
Viral Vector Services
Plasmid DNA (pDNA) Materials
To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing.
Plasmid Offering
mRNA Manufacturing
AGC Biologics leveraged its 25+ years of experience in microbial, drug substance, and pDNA manufacturing to create our Messenger RNA (mRNA) service line. We manufacture high-quality mRNA in R&D and GMP grades for some of the most demanding applications in the industry today, and offer customized process development services based on your specific mRNA and host system needs.
mRNA Services
Fill out the form below to request a meeting during the event
